Literature DB >> 33613282

Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro.

Hua-Long Xiong1, Jia-Li Cao1,2, Chen-Guang Shen3,4, Jian Ma1, Xiao-Yang Qiao1, Tian-Shu Shi1, Sheng-Xiang Ge1, Hui-Ming Ye2, Jun Zhang1, Quan Yuan1, Tian-Ying Zhang1, Ning-Shao Xia1.   

Abstract

To identify drugs that are potentially used for the treatment of COVID-19, the potency of 1403 FDA-approved drugs were evaluated using a robust pseudovirus assay and the candidates were further confirmed by authentic SARS-CoV-2 assay. Four compounds, Clomiphene (citrate), Vortioxetine, Vortioxetine (hydrobromide) and Asenapine (hydrochloride), showed potent inhibitory effects in both pseudovirus and authentic virus assay. The combination of Clomiphene (citrate), Vortioxetine and Asenapine (hydrochloride) is much more potent than used alone, with IC50 of 0.34 μM.
Copyright © 2021 Xiong, Cao, Shen, Ma, Qiao, Shi, Ge, Ye, Zhang, Yuan, Zhang and Xia.

Entities:  

Keywords:  SARS-CoV-2; drug combination; drug screening; pseudovirus assay; vesicular stomatitis virus

Year:  2021        PMID： 33613282      PMCID： PMC7892437          DOI： 10.3389/fphar.2020.609592

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN： 1663-9812            Impact factor:   5.810


  11 in total

1.  Screening for inhibitors against SARS-CoV-2 and its variants.

Authors:  Weijing Yuan; Xiaojing Dong; Lan Chen; Xiaobo Lei; Zhuo Zhou; Li Guo; Jianwei Wang
Journal:  Biosaf Health       Date:  2022-05-07

2.  Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19.

Authors:  Sung-Ting Chuang; Henrietta Papp; Anett Kuczmog; Rebecca Eells; Jose M Condor Capcha; Lina A Shehadeh; Ferenc Jakab; Peter Buchwald
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-18

3.  Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters.

Authors:  Keisuke Kuroda; Cong Li; Kiran Dhangar; Manish Kumar
Journal:  Sci Total Environ       Date:  2021-02-15       Impact factor: 7.963

4.  Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.

Authors:  Bruno O Villoutreix; Rajagopal Krishnamoorthy; Ryad Tamouza; Marion Leboyer; Philippe Beaune
Journal:  Adv Appl Bioinform Chem       Date:  2021-04-12

5.  Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.

Authors:  Shiu-Wan Chan; Talha Shafi; Robert C Ford
Journal:  Viruses       Date:  2021-11-19       Impact factor: 5.048

6.  Metallodrug Profiling against SARS-CoV-2 Target Proteins Identifies Highly Potent Inhibitors of the S/ACE2 interaction and the Papain-like Protease PLpro.

Authors:  Maria Gil-Moles; Sebastian Türck; Uttara Basu; Andrea Pettenuzzo; Saurav Bhattacharya; Ananthu Rajan; Xiang Ma; Rolf Büssing; Jessica Wölker; Hilke Burmeister; Henrik Hoffmeister; Pia Schneeberg; Andre Prause; Petra Lippmann; Josephine Kusi-Nimarko; Storm Hassell-Hart; Andrew McGown; Daniel Guest; Yan Lin; Anna Notaro; Robin Vinck; Johannes Karges; Kevin Cariou; Kun Peng; Xue Qin; Xing Wang; Joanna Skiba; Łukasz Szczupak; Konrad Kowalski; Ulrich Schatzschneider; Catherine Hemmert; Heinz Gornitzka; Elena R Milaeva; Alexey A Nazarov; Gilles Gasser; John Spencer; Luca Ronconi; Ulrich Kortz; Jindrich Cinatl; Denisa Bojkova; Ingo Ott
Journal:  Chemistry       Date:  2021-11-23       Impact factor: 5.020

7.  Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor.

Authors:  Hemant Suryavanshi; Raju D Chaudhari; Vishakha Patil; Swapan Majumdar; Sudhan Debnath; Goutam Biswas
Journal:  Daru       Date:  2022-05-04       Impact factor: 4.088

Review 8.  Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence.

Authors:  Marta Mas; Juan Antonio García-Vicente; Anaïs Estrada-Gelonch; Clara Pérez-Mañá; Esther Papaseit; Marta Torrens; Magí Farré
Journal:  J Clin Med       Date:  2022-07-12       Impact factor: 4.964

Review 9.  The Spike of SARS-CoV-2: Uniqueness and Applications.

Authors:  Ranjith Kumavath; Debmalya Barh; Bruno Silva Andrade; Madangchanok Imchen; Flavia Figueira Aburjaile; Athira Ch; Diego Lucas Neres Rodrigues; Sandeep Tiwari; Khalid J Alzahrani; Aristóteles Góes-Neto; Marianna E Weener; Preetam Ghosh; Vasco Azevedo
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

10.  Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection.

Authors:  Gwenolé Loas; Pascal Le Corre
Journal:  Pharmaceuticals (Basel)       Date:  2021-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.